Bing Yuan, OnCusp Therapeutics CEO
January 4, 2024 09:25 AM EST
Financing
Startups
China

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Kyle LaHucik

Senior Reporter

The an­ti­body-drug con­ju­gate news keeps flow­ing: On­Cusp Ther­a­peu­tics is the lat­est to join the are­na with an over­sub­scribed $100 mil­lion Se­ries A

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times